Allarity Therapeutics provides update on dovitinib program for renal cell carcinoma.
Read time: 1 mins
Last updated:26th Oct 2020
Published:24th Oct 2020
Allarity Therapeutics A/S announced several updates related to its planned filing of a new drug application (NDA) with the FDA for dovitinib, a pan-tyrosine kinase inhibitor (TKI) that is one of Allarity’s priority programs.
Condition: Renal Cell Carcinoma